Method for Targeting Antigens to Specific Presenting Cells Enhances Immune Regulation
Tech ID: 95-01
Summary - A variety of antigen-presenting cells play critical roles in determining the type and effectiveness of immune responses elicited by antigens. Researchers at National Jewish Health have developed a method to target specific antigen presenting cells with peptides to yield a more predictable and efficient immune response.
Potential Applications - Potential to develop improved immunization, tolerance, or therapeutic approaches for a wide variety of conditions and clinical applications
Advantages of Invention
- Specific targeting to optimal presenting cell types may: allow for reduced antigen dosage; yield more consistent response, and avoid undesired side effects.
- Reduction or elimination of the need for adjuvants in vaccines, which may cause unwanted side effects.
- Allows introduction of antigens that would otherwise stimulate a pre-existing autoimmunity.
State of Development - Prototype DNA constructs for ovalbumin have been developed and demonstrated in vitro.
Further R&D Required - Further testing and extension to other peptides
Licensing Potential - This technology is available for licensing.
Patent Status - U.S. Patent # 5,698,679.
Inventor - David Nemazee, PhD
For Further Information, Contact:
Emmanuel Hilaire, PhD
Licensing Associate
Intellectual Property and Technology Commercialization Program
National Jewish Health
1400 Jackson Street, Room M206a
Denver, CO 80206
Voice: (303) 398-1053
Fax: (303) 270-2352
hilairee@njc.org
